|Videos|December 15, 2022
Acne Treatment Selection Considerations
Author(s)Zoe Diana Draelos, MD
An expert in acne management shares her insight into the patient characteristics a provider needs to consider when assessing the risk/benefit of a therapeutic agent for the management of acne.
Advertisement
Episodes in this series
Advertisement
Related to this article
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.
This review of the latest dermatological studies includes insights on
Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.
Advertisement
Advertisement
Trending on Dermatology Times
1
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
2
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
5